Deborah Harland, Vice President and Partner at SR One, writes in the foreword to our new report into corporate venture capital in UK biotech that there is a clear opportunity to establish the UK as a European biotech hub.
Since I established the European office of SR One in 2005, GSK's corporate venture arm has been one of the leading investors in European biotech alongside our peers from Johnson & Johnson, Novartis Venture Fund and an expanding group of other corporate equity investors.
This report highlights the acceleration of corporate equity investing in European biotech over the last decade, and most notably the growth observed in the UK. The findings are consistent with data from the US where a recent analysis confirmed the critically important contribution of corporate venture capital (CVC) and direct corporate investing for start-up and emerging biotech companies over the past 15 years, and importantly, the correlation between corporate investor involvement and successful 'exit' outcomes.
While the investments made by SR One and our CVC peers leverage significant further private investment into Europe, the report illustrates that SR One is among a small minority of CVCs both actively investing and with investor decision-makers present on the ground in the UK. There is therefore a clear opportunity to consider how best to establish the UK as the preferred location for corporates investing in Europe, secure continued growth of CVC as a funding source for early-stage biotech companies and enable the translation of a broader footprint of innovative science into potential new medicines.
Deborah Harland, Vice President and Partner at SR One
 LifeSci VC: Corporate Equity Investing in Biotech, 10 March 2016.